DCLK3 and acute myeloid leukemia: Simultaneous resistance to CLR and MTZ was present in 28.3% of the 53 treatment-naïve patients, and in 52.9% of the 34 pediatric patients with previous treatment in this study, suggesting that the concomitant regimen (PPI, AML, CLR, and MTZ) might not be suitable as empiric therapy for these pediatric patients.